Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AcelRx’s Pain Drug Zalviso Delayed By Delivery Device Issues

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s “complete response” letter asks the company to reduce the rate of optical errors and improve the instructions for use of the patient-activated, hand-held analgesic system.

You may also be interested in...



AcelRx Baffled By Zalviso Trial Request On Opioid Dispensing Problems

FDA asked for clinical study before reviewing data AcelRx generated after previous ‘complete response,’ CEO King said.

AcelRx Baffled By Zalviso Trial Request On Opioid Dispensing Problems

FDA asked for clinical study before reviewing data AcelRx generated after previous ‘complete response,’ CEO King said.

AcelRx Tries Transparency To Reassure Investors After Zalviso ‘Complete Response’

Trying to beat The Medicines Co. to market with a patient-administered post-surgical pain analgesic, AcelRx hopes it can refile the NDA for Zalviso by the end of 2014, based on already-filed amendments and adjustments to the delivery mechanism and instructions for use.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS077490

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel